Operating at the nanoscale affords size- and structure- related behaviors that differ significantly from those of bulk materials and which can have significant therapeutic advantage.

To evolve nanotherapeutics as efficient immunotherapeutic drug substances, we are studying and developing polymeric and liposomal nanoparticles to improve their biological function, targeting ability and therapeutic efficacy. Starting from the utilization of nanoparticles as delivery tools for protein and nucleic acid-based therapeutics, we aim to develop sophisticated nanomachines that can provide sustained therapeutic benefit in vivo.

We leverage nanotechnology to fuel the development of innovative next-generation immunotherapies that metabolically and functionally suppress the tumor microenvironment's inhibitory action on the immune system.